Careteq (ASX:CTQ) DeferredTaxAndRevenue: A$0.10 Mil (As of Dec. 2025)


What is Careteq DeferredTaxAndRevenue?

Careteq ASX:CTQ +8.33% DeferredTaxAndRevenue is A$0.10 Mil as of Dec. 2025. The stock has 6 warning signs investors should review.

Deferred Tax And Revenue represents the current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Careteq's current deferred tax and revenue for the quarter that ended in Dec. 2025 was A$0.10 Mil.

Careteq DeferredTaxAndRevenue Related Terms

Careteq DeferredTaxAndRevenue Historical Data

* Premium members only.

The historical data trend for Careteq's DeferredTaxAndRevenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Careteq DeferredTaxAndRevenue Chart

Careteq Annual Data
Trend Jun21 Jun22 Jun23 Jun24 Jun25
DeferredTaxAndRevenue
0.05 0.00 0.30 0.48 0.12

Careteq Semi-Annual Data
Jun21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
DeferredTaxAndRevenue Get a 7-Day Free Trial Premium Member Only 0.00 0.48 0.51 0.12 0.10
Frequently Asked Questions Learn more about DeferredTaxAndRevenue →
What does a DeferredTaxAndRevenue of A$0.10 Mil mean?
Careteq (ASX:CTQ) has a DeferredTaxAndRevenue of A$0.10 Mil as of Dec. 2025. Deferred tax and revenue represents the current portion of taxes and unearned revenue that are now past due. View historical data on Careteq.
Is Careteq's DeferredTaxAndRevenue too high?
Careteq's current DeferredTaxAndRevenue is A$0.10 Mil.
How does Careteq's DeferredTaxAndRevenue compare to VEEV and BTSG?
Careteq's DeferredTaxAndRevenue of A$0.10 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good DeferredTaxAndRevenue for a Healthcare Providers & Services company?
A good DeferredTaxAndRevenue depends on the Healthcare Providers & Services industry context. However, DeferredTaxAndRevenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high DeferredTaxAndRevenue mean?
A high DeferredTaxAndRevenue can signal that a stock is expensive relative to its fundamentals. Deferred tax and revenue represents the current portion of taxes and unearned revenue that are now past due. View historical data on Careteq. Careteq's current DeferredTaxAndRevenue is A$0.10 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Careteq stock overvalued right now?
Based on GuruFocus' analysis, Careteq (ASX:CTQ) is currently considered Modestly Overvalued. The stock's GF Value™ is A$0.01, compared to a current price of A$0.01 — trading 30% above its estimated fair value. The current DeferredTaxAndRevenue is A$0.10 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is DeferredTaxAndRevenue calculated?
DeferredTaxAndRevenue is calculated from a company's financial statements. For Careteq (ASX:CTQ), the current DeferredTaxAndRevenue is A$0.10 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Careteq Business Description

Address 99 Queen Street, Level 10, Melbourne, VIC, AUS, 3000
Careteq Ltd provides Residential Medication Management Review and Home Medicines Review services as part of the Medication Management Programs, generating revenue from medication review, education, and support services. The company focuses on medication management and home care solutions to provide continuity of care and improve clinical outcomes for patients through Home Medication Reviews. Medication-related harm includes adverse drug reactions, medication errors, and complications that jeopardise patient safety and increase healthcare costs. The company operates in Australia.